Current Research in Translational Medicine最新文献

{"title":"Exploring clues pointing toward the existence of a brain-gut microbiota-hair follicle axis","authors":"Yang Feng","doi":"10.1016/j.retram.2023.103408","DOIUrl":"10.1016/j.retram.2023.103408","url":null,"abstract":"<div><p><span><span>Proposing the concept of a brain-gut-skin axis has led some researchers to recognize the relationship among brain activity, gut microbiota, and the skin. </span>Hair follicles<span><span> are skin accessory organs, a previously unnoticed target tissue for classical neurohormones<span>, neurotrophins, and </span></span>neuropeptides<span>. Some studies have shown a relationship between the central nervous system and hair follicles that an imbalance in the gut bacteria can affect hair follicle density. This review summarizes existing evidence from literature and explores clues supporting a connection linking the brain, gut microbiota, and hair follicles. It amalgamates previously proposed partial concepts into a new, unified concept—the “brain-gut microbiota-hair follicle” axis, —which suggests that modulation of the </span></span></span>microbiome<span> via probiotics can have positive effects on hair follicles. This review also explores how preclinical research on hair follicles can propel novel and clinically untapped applications.</span></p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 1","pages":"Article 103408"},"PeriodicalIF":4.1,"publicationDate":"2023-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135248858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploration of the mechanism of reinfusion of fresh autologous blood in type 2 diabetic body to induce macrophage polarization and inhibit erythrocyte damage","authors":"She-jun Hu, Jia-ming Xu, Man-di Wu, Ke Yue, Ying-hui Cui, Yu Bai, Lai-wei You, Jian-Rong Guo","doi":"10.1016/j.retram.2023.103415","DOIUrl":"https://doi.org/10.1016/j.retram.2023.103415","url":null,"abstract":"Type 2 diabetes (T2D) triggers an inflammatory response that can damage red blood cells. M2 macrophages have inhibitory effects on inflammation and play an important role in tissue damage repair and fibrosis. Autologous blood transfusion has the potential to inhibit red blood cell damage by mediating macrophage polarization. Swiss mice were used to establish a suitable type 2 diabetes model and autologous blood transfusion was performed. The mice were executed, the blood of the mice was collected, and CD14+ monocytes were sorted. The expression levels of phenotypic molecules CD16, CD32 and CD206 in CD14+ monocytes were analyzed by flow cytometry. The proportion of M1 and M2 macrophages were analyzed by flow cytometry. The Q value, P50, 2,3-DPG and Na+-K+-ATPase of red blood cells were detected. The red blood cell osmotic fragility test analyzed the RBC osmotic fragility. Western Blot analysis was used to analyze the expression changes of erythrocyte surface membrane proteins or transporters EPB41, S1P, GLTP and SPPL2A. Autologous blood transfusion induced a significant increase in the number of macrophages. The state and capacity of blood cells improved with autologous blood transfusion. Reinfusion of fresh autologous blood in T2D body made erythrocytes shrank. The expression of erythrocyte-related proteins proved that the erythrocyte injury in the Fresh+T2D group was significantly reduced. The reinfusion of fresh autologous blood into the body of patients with type 2 diabetes can induce macrophage polarization to M2, thereby inhibiting red blood cell damage.","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"117 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135588287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant","authors":"P Sriskandarajah ,&nbsp;D P McLornan ,&nbsp;C Oni ,&nbsp;AJ Wilson ,&nbsp;C Woodley ,&nbsp;M Ciesielska ,&nbsp;K Raj ,&nbsp;R Dillon ,&nbsp;M Ethell ,&nbsp;J Chacko ,&nbsp;K Orchard ,&nbsp;DH Radia","doi":"10.1016/j.retram.2023.103398","DOIUrl":"10.1016/j.retram.2023.103398","url":null,"abstract":"<div><p><span>Advanced systemic mastocytosis<span> (AdvSM) is a rare, life-limiting mast cell (MC) neoplasm, with approximately 70% patients having an associated haematological neoplasm (AHN). Avapritinib<span>, a selective tyrosine kinase inhibitor targeting KIT D816V, has shown potent activity </span></span></span>translating clinically into durable responses in the phase 1 EXPLORER (NCT02561988) and phase 2 PATHFINDER (NCT03580655) studies.</p><p>We report three patients with AdvSM-AHN on avapritinib who achieved complete remission (CR) of SM and were successfully bridged to allogeneic haematopoietic cell<span> transplant (allo-HCT). Two cases additionally highlight the risk of clonal evolution<span> within the AHN component and requirement for close monitoring while on targeted therapy.</span></span></p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103398"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9655660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexistence of three hematological malignancies in association with a first time documented mutation: “One train can hide another”°, and even more!","authors":"Tamim Alsuliman ,&nbsp;Souhila Ikhlef ,&nbsp;Nicolas Stocker ,&nbsp;Fazia Kaoui ,&nbsp;Laure Ricard ,&nbsp;Malek Aoudjhane ,&nbsp;Mohamad Mohty ,&nbsp;Zora Marjanovic","doi":"10.1016/j.retram.2023.103403","DOIUrl":"10.1016/j.retram.2023.103403","url":null,"abstract":"<div><p>Coexisting malignancies is not only an uncommon event but, it can also represent a medical challenge. Its complexity relies on the difficulty of management and the need for personalized and prioritized therapeutic approaches, on the one hand, and in the potential misdiagnosis of recurrence or even a de novo disease, on the other.</p><p>Here, we present a case of a 69-year-old patient, who was initially diagnosed with a chronic myelomonocytic leukemia (CMML), followed by monoclonal gammopathy<span> of uncertain significance (MGUS). Few years later, the patient developed Hodgkin's lymphoma (HL), and a new mutation, previously undocumented in the medical literature, was also detected.</span></p><p><span>As a conclusion, we can say that the decision must be taken with caution and must be based on two major factors: 1- The rapid evolution of malignancies: give priority to treating the most rapid/life-threatening disease. 2- Prioritize the treatment of symptomatic disease and/or that which may most improve patients’ </span>quality of life.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103403"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9873285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment and characterization of a novel breast implant-associated anaplastic large cell lymphoma cell line and PDX model (BIA-XR1) with a unique KRAS mutation","authors":"Ioanna Xagoraris ,&nbsp;Konstantina Stathopoulou ,&nbsp;Roberta D' Aulerio ,&nbsp;Minghui He ,&nbsp;Anett Ketscher ,&nbsp;Kenbugul Jatta ,&nbsp;Felix Haglund de Flon ,&nbsp;Gisela Barbany ,&nbsp;Richard Rosenquist ,&nbsp;Lisa S. Westerberg ,&nbsp;George Z. Rassidakis","doi":"10.1016/j.retram.2023.103401","DOIUrl":"10.1016/j.retram.2023.103401","url":null,"abstract":"<div><p>Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell lymphoma type with distinct clinical, molecular and genetic features. Establishment of BIA-ALCL cell lines and patient-derived xenograft (PDX) models are essential experimental tools to investigate the molecular pathogenesis of the disease. We characterized a novel BIA-ALCL cell line and PDX model, named BIA-XR1, derived from a patient with textured breast implant who developed lymphoma. Next-generation sequencing revealed a <em>STAT3</em> mutation, commonly detected in BIA-ALCL, and a unique <em>KRAS</em> mutation reported for the first time in this lymphoma type. Both JAK/STAT3 and RAS/MEK/ERK oncogenic pathways were activated in BIA-XR1, which are targetable with clinically available agents.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103401"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9680246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Splenic irradiation prior to allogeneic transplant conditioning in myelofibrosis: A pilot experience","authors":"Edoardo Campodonico ,&nbsp;Elisabetta Xue ,&nbsp;Simona Piemontese ,&nbsp;Anna Chiara ,&nbsp;Alessandro Bruno ,&nbsp;Gianluca Scorpio ,&nbsp;Rosamaria Nitti ,&nbsp;Daniele Sannipoli ,&nbsp;Giorgio Orofino ,&nbsp;Paolo Fiore ,&nbsp;Maria Chiara Quattrocchi ,&nbsp;Elisa Diral ,&nbsp;Daniela Clerici ,&nbsp;Francesca Farina ,&nbsp;Consuelo Corti ,&nbsp;Francesca Lunghi ,&nbsp;Maria Teresa Lupo-Stanghellini ,&nbsp;Nadia Di Muzio ,&nbsp;Fabio Ciceri ,&nbsp;Raffaella Greco ,&nbsp;Jacopo Peccatori","doi":"10.1016/j.retram.2023.103400","DOIUrl":"10.1016/j.retram.2023.103400","url":null,"abstract":"<div><h3>Introduction</h3><p>In the era of JAK inhibitors<span><span><span><span>, allogeneic stem cell transplantation (HSCT) remains the only curative </span>treatment for patients with </span>Myelofibrosis (MF). Splenic irradiation (SI) may be used to reduce </span>spleen size and related symptoms.</span></p></div><div><h3>Methods</h3><p><span><span><span><span>We conducted a retrospective analysis on 14 patients with MF who underwent HSCT with SI from any donor source at our center between June 2016 and March 2021. All patients received a conditioning </span>backbone based on </span>treosulfan and </span>fludarabine<span>, with post-transplant cyclophosphamide (PTCy) and </span></span>sirolimus as graft-versus-host disease (GvHD) prophylaxis. Patients received SI with 10 Gy involved-field radiotherapy in five 2-Gy fractions over the course of a week prior to the beginning of conditioning.</p></div><div><h3>Results</h3><p><span>At transplant all patients were transfusion-dependent and had splenomegaly (median bipolar diameter by ultrasound: 20.75 cm). Overall, 12 patients had received </span>ruxolitinib prior to transplant. Re-evaluation of spleen dimensions was available for 13 patients: median splenic bipolar diameter after at least 3 months from transplant decreased by a median of 25%. With a median post-transplant follow-up of 25 months, 6 patients remain in CR with full-donor chimerism, 3 patients died due to NRM. Overall, 4 patients relapsed. At last follow-up, nine patients are currently alive and achieved transfusion-independence.</p></div><div><h3>Conclusions</h3><p>In a small cohort of mostly ruxolitinib pre-treated patients, SI and treosulfan-based conditioning appeared a safe and effective tool to reduce spleen dimensions and ameliorate symptoms. Future prospective studies with adequate sample size are warranted to further investigate the usefulness and safety of this approach in MF.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103400"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9655659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary prevention of cancer-associated venous thrombosis: Rationale and challenges in clinical practice","authors":"Ismail Elalamy ,&nbsp;Alain Cohen-Solal ,&nbsp;Olivier Hanon ,&nbsp;Mariana Mirabel ,&nbsp;Patrick Mismetti ,&nbsp;Jean-Philippe Spano","doi":"10.1016/j.retram.2023.103405","DOIUrl":"10.1016/j.retram.2023.103405","url":null,"abstract":"<div><p>Cancer-associated venous thrombosis (CAT) is a common, multifactor event known to complicate the course of cancer and jeopardize a patient's prognosis. The current guidelines regarding the prevention of CAT are sometimes considered insufficiently precise about specific situations, or are poorly applied. The expected benefits of thromboprophylaxis are balanced by the risk of major bleeding induced by anticoagulation, which implies a need to accurately identify ambulatory patients at high risk of thrombosis or hemorrhage. The Khorana score is commonly used for this, but is limited by the non-reproducibility of predicted performance across cancer types, and by the fact that antitumor treatment and cardiovascular risks are not included. The COMPASS-CAT score, which includes those two aspects, was found to be a more accurate predictor of venous thromboembolism in patients with lung cancer, and to better distinguish between patients at low or high risk of thrombosis. The frailty of patients with cancer is also a major issue, and should be taken into account when thromboprophylaxis is considered. According to current guidelines, CAT prophylaxis should be considered for hospitalized patients, those for whom surgery is scheduled, or those with pancreatic cancers. In ambulatory patients, decisions should be made according to patient, cancer and antitumoral treatment characteristics. Low molecular weight heparin is the gold standard of CAT prophylaxis. Despite increased risks of bleeding or drug-drug interactions in cancer patients, direct oral anticoagulants could be alternate options for high-risk ambulatory patients that should be accompanied by a careful global analysis of benefits, harms, and patient preferences.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103405"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9851704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of interim PET/CT as predictor of outcome in newly diagnosed diffuse large b-cell lymphoma in the chemo-immunotherapy era","authors":"Moussab Damlaj ,&nbsp;Waed Jaber ,&nbsp;Afnan Al Najjar ,&nbsp;Sumayyah Altamimi ,&nbsp;Tarfa Al Onazi ,&nbsp;Mohammed Alzayed ,&nbsp;Ahmad Damlaj ,&nbsp;Rehab Yassin ,&nbsp;Bader Alahmari ,&nbsp;Ayman Alhejazi ,&nbsp;Giamal Gmati ,&nbsp;Khadega Abuelgasim ,&nbsp;Hind Salama ,&nbsp;Ahmed Alaskar ,&nbsp;Mohsen Al Zahrani","doi":"10.1016/j.retram.2023.103406","DOIUrl":"10.1016/j.retram.2023.103406","url":null,"abstract":"","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103406"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9931921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone marrow alterations in COVID-19 infection: The root of hematological problems","authors":"Fatemeh Zeylabi M.Sc. ,&nbsp;Najmeh Nameh Goshay Fard M.D. ,&nbsp;Abazar Parsi M.D. ,&nbsp;Seyed Mohammad Sadegh Pezeshki Ph.D.","doi":"10.1016/j.retram.2023.103407","DOIUrl":"10.1016/j.retram.2023.103407","url":null,"abstract":"<div><h3>Introduction</h3><p><span><span>The 2019 coronavirus disease (COVID-19) is a respiratory infection caused by the SARS-CoV-2 </span>virus<span><span> with a significant impact on the hematopoietic system and </span>homeostasis. The effect of the virus on </span></span>blood cells indicates the involvement of the bone marrow (BM) as the place of production and maturation of these cells by the virus and it reminds the necessity of investigating the effect of the virus on the bone marrow.</p></div><div><h3>Method</h3><p>To investigate the effects of COVID-19 infection in BM, we reviewed literature from the Google Scholar search engine and PubMed database up to 2022 using the terms \"COVID-19; SARS-CoV-2; Bone marrow; Thrombocytopenia; Hemophagocytosis<span>; Pancytopenia and Thrombocytopenia.</span></p></div><div><h3>Results</h3><p>Infection with the SARS-CoV-2 virus is accompanied by alterations such as single-line cytopenia<span><span><span>, pancytopenia, hemophagocytosis, and BM necrosis. The presence of factors such as </span>cytokine release syndrome, the direct effect of the virus on cells through different receptors, and the side effects of current </span>treatments such as corticosteroids are some of the important mechanisms in the occurrence of these alterations.</span></p></div><div><h3>Conclusion</h3><p>To our knowledge, this review is the first study to comprehensively investigate BM alterations caused by SAR-CoV-2 virus infection. The available findings show that the significant impact of this viral infection on blood cells and the clinical consequences resulting from them are deeper than previously thought and it may be rooted in the changes that the virus causes in the BM of patients.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103407"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9943393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in adoptive T-cell therapy for metastatic melanoma","authors":"Aparimita Das ,&nbsp;Aruni Ghose ,&nbsp;Kevin Naicker ,&nbsp;Elisabet Sanchez ,&nbsp;Cyrus Chargari ,&nbsp;Elie Rassy ,&nbsp;Stergios Boussios","doi":"10.1016/j.retram.2023.103404","DOIUrl":"10.1016/j.retram.2023.103404","url":null,"abstract":"<div><p><span>Adoptive T cell<span><span> therapy (ACT) is a fast developing, niche area of immunotherapy (IO), which is revolutionising the therapeutic landscape of </span>solid tumour oncology<span>, especially metastatic melanoma<span> (MM). Identifying tumour antigens<span><span><span> (TAs) as potential targets, the ACT response is mediated by either Tumour Infiltrating Lymphocytes (TILs) or genetically modified T cells with specific receptors – </span>T cell receptors (TCRs) or </span>chimeric antigen receptors (CARs) or more prospectively, natural killer (NK) cells. </span></span></span></span></span>Clinical trials involving ACT in MM from 2006 to present have shown promising results. Yet it is not without its drawbacks which include significant auto-immune toxicity and need for pre-conditioning lymphodepletion. Although immune-modulation is underway using various combination therapies in the hope of enhancing efficacy and reducing toxicity. Our review article explores the role of ACT in MM, including the various modalities – their safety, efficacy, risks and their development in the trial and the real world setting.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103404"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9851703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}